E nhancers shape gene expression programs by coalescing information from environmental stimuli and the coordinated activities of transcription factors and cofactors [1] [2] [3] [4] [5] . The ability to annotate enhancers and their activity states stems from the identification of epigenomic signatures that include an accumulation of the histone mark histone H3 lysine 4 monomethylation (H3K4me1), which, together with histone H3 lysine 27 acetylation (H3K27ac), demarcates active enhancers 3, [6] [7] [8] [9] . A number of transcriptional coregulators bind to acetylated histones through BD modules to affect chromatin accessibility and transcriptional activation at active enhancers 10, 11 . The affinity and selectivity of BD interactions with acetylated lysines are typically weak, but can be increased by BD interactions with multiple acetylation sites in the histone tail [12] [13] [14] , suggesting that additional mechanisms regulating BD binding at enhancers are likely to have important implications for chromatin and gene regulation.
nhancers shape gene expression programs by coalescing information from environmental stimuli and the coordinated activities of transcription factors and cofactors [1] [2] [3] [4] [5] . The ability to annotate enhancers and their activity states stems from the identification of epigenomic signatures that include an accumulation of the histone mark histone H3 lysine 4 monomethylation (H3K4me1), which, together with histone H3 lysine 27 acetylation (H3K27ac), demarcates active enhancers 3, [6] [7] [8] [9] . A number of transcriptional coregulators bind to acetylated histones through BD modules to affect chromatin accessibility and transcriptional activation at active enhancers 10, 11 . The affinity and selectivity of BD interactions with acetylated lysines are typically weak, but can be increased by BD interactions with multiple acetylation sites in the histone tail [12] [13] [14] , suggesting that additional mechanisms regulating BD binding at enhancers are likely to have important implications for chromatin and gene regulation.
BET proteins bind to histone acetylation marks via their tandem BDs (BD1 and BD2) 10, 15 . BRD4, a well-studied member of the BET family, binds to acetylated histones and non-histone proteins at enhancers and promoters 10, [16] [17] [18] to regulate gene expression programs that have pivotal roles in inflammation and cancer development [19] [20] [21] . BRD4 has been shown to associate with transcriptional regulators, including TWIST, p53, C/EBPα , C/EBPβ , ERG, and NF-κ B, providing increasing support for its role in enhancer and gene regulation [22] [23] [24] [25] [26] [27] [28] . Selective inhibitors of the BET family, including JQ1 29 , have demonstrated that BRD4 binding at enhancers supports super-enhancer formation 25, 30, 31 . BRD4 also promotes RNA polymerase II (Pol II) elongation through its recruitment of active positive elongation factor-b (P-TEFb) 32, 33 and its histone chaperone activity 34 , which affects the production of eRNAs 34, 35 . Although there are clear links between BRD4 and gene regulation, the mechanisms underlying the enhancer-and gene-specific targeting and functions of BRD4 remain elusive.
eRNAs have been implicated in the regulation of gene expression in multiple cell types and in response to different stimuli [36] [37] [38] [39] [40] [41] [42] [43] [44] . Recent studies have linked eRNAs to the regulation of enhancer-promoter interaction interfaces 38, 41 , chromatin remodeling 43 , RNA Pol II pause release 45 , and the recruitment of general cofactors that include cohesin 38, 41 , Mediator 46 , and CBP 47 . Although eRNAs are well positioned to add a layer of complexity to enhancer and gene regulation, the molecular basis by which they function remains poorly understood.
We found that BDs function as RNA-binding modules. Notably, we found that eRNAs exhibited cooperativity with acetylated histone lysines in vitro and at active enhancers to augment BRD4 binding and transcriptional activity. Collectively, our results provide evidence for a feed-forward epigenetic mechanism in which eRNAs, via BRD4 interactions, support an active enhancer landscape that modulates proinflammatory gene expression.
Results

BRD4 binds and functions at p53 R273H,P309S
-bound enhancers in response to immune signaling. We sought to investigate whether BRD4 regulates recently identified enhancers that are activated by p53 R273H,P309S in response to chronic immune signaling 44 . Using genome-wide chromatin immunoprecipitation followed by sequencing (ChIP-seq) in human SW480 colon cancer cells expressing p53 R273H,P309S (hereafter mutp53) and treated with tumor necrosis factor alpha (TNF-α ) for 16 h, we identified stringent BRD4-binding peaks (n = 21,528, P < 10
−5
). Comparative analyses of the BRD4 peaks with previously published mutp53, H3K4me1, and H3K27ac ChIP-seq data in response to chronic TNF-α signaling 44 showed colocalization of BRD4 binding peaks with the peak sites for mutp53 at intergenic sites showing enrichment of H3K4me1 and H3K27ac (Fig. 1a) . We found that approximately one-third (28%, n = 5,949, P < 10 ) of the BRD4-bound enhancers were also occupied by mutp53 ( Supplementary Fig. 1a ). Furthermore, de novo motif analysis revealed that among the most highly enriched motifs to overlap with BRD4 and mutp53 peaks were those recognized by NF-κ B/p65 and EWS-ERG fusion (ETS) ( Supplementary  Fig. 1b) , consistent with our previous findings that NF-κ B recruits mutp53 to active enhancers in response to chronic immune signaling 44 . We also performed sequential ChIP followed by qPCR using primer sets against downstream control regions (amplicon B) and the enhancer (amplicon A) regions of MMP9 and CCL2, which are among the enhancers that we previously found to be activated by mutp53 and NF-κ B in response to chronic TNF-α signaling 44 . These assays revealed simultaneous binding of mutp53 and BRD4 at the MMP9 and CCL2 enhancers, but not the control regions, in response to chronic TNF-α signaling ( Supplementary Fig. 1c ). Using coimmunoprecipitation, we found that BRD4 and mutp53 formed physiological associations in SW480 cells before and after TNF-α treatment ( Supplementary Fig. 1d ). Using purified proteins, we also found that BRD4 formed direct interactions with p53 R273H and wild-type (WT) p53 ( Supplementary Fig. 1e ), which is similar to previous findings of BRD4 interactions with WT p53 24 . We next assessed mutp53 contributions to BRD4 binding at enhancers by ChIP-qPCR analyses in SW480 cells expressing doxycycline-inducible shRNAs against mutp53 following TNF-α treatment for 16 h. Relative to a non-targeting shRNA against LacZ (Ctrl), p53 shRNA markedly reduced mutp53 protein levels after TNF-α treatment without affecting BRD4 protein levels ( Supplementary Fig. 1f ). mutp53 knockdown resulted in a comparable loss of mutp53 binding at the MMP9 (66%) and CCL2 (72%) enhancer regions that resulted in a significant reduction in BRD4 binding at the MMP9 (52%) and CCL2 (65%) enhancers (Fig. 1b) . Together, these results establish functional mutp53-BRD4 interactions and underscore the requirement for mutp53 in regulating BRD4 binding at active enhancers in response to chronic TNF-α signaling.
We next examined the global levels of nascent transcription ( ± TNF-α ) centered on the enhancer-specific BRD4 and mutp53 ChIP-seq peaks using our global run-on sequencing (GRO-seq) data 44 . We observed markedly induced eRNA levels following 16 h of TNF-α treatment at H3K27ac-enriched intergenic sites that were co-occupied by BRD4 and mutp53 (Fig. 1c) . Notably, the TNFinduced eRNA levels observed at the mutp53 and BRD4 co-bound enhancers were significantly higher than the TNF-induced eRNA levels at H3K27ac-enriched intergenic sites that were not co-bound by BRD4 and mutp53 (Fig. 1c) . To determine whether there is a direct role for BRD4 in the regulation of TNF-α -induced enhancer transcription, we established SW480 cells stably expressing nontargeting shRNA (Ctrl) or two different shRNAs specific to BRD4 (BRD4-1 and BRD4-2). Relative to the control knockdown, both BRD4 shRNAs decreased BRD4 mRNA and protein levels (Fig. 1d) . ChIP-qPCR analyses in control knockdown cells ( ± TNF-α ) revealed that BRD4 binding at the MMP9 and CCL2 enhancers was increased (53% and 70%, respectively) in response to chronic TNF-α signaling (Fig. 1e) . As expected, BRD4 knockdown resulted in a significant loss of TNF-α -inducible BRD4 binding at the MMP9 and CCL2 enhancers (55% and 63%, respectively; Fig. 1e ) that resulted in a significant decrease in MMP9 and CCL2 eRNA levels (fourfold and sixfold, respectively) and a twofold decrease in the mRNA levels of both genes (Fig. 1f) . Under uninduced conditions, BRD4 knockdown had little to no effect on BRD4 binding and the eRNA/mRNA expression levels at the MMP9 and CCL2 enhancers (Fig. 1e,f) . The decreased expression of MMP9 and CCL2 eRNAs and mRNAs following BRD4 knockdown was independent of a decrease in mutp53 binding at the MMP9 and CCL2 enhancers ( Supplementary Fig. 1h ), which, taken together with our mutp53 knockdown analyses (Fig. 1b) , indicates that, although mutp53 affects BRD4 binding, BRD4 is not required for mutp53 binding at the MMP9 and CCL2 enhancers. Consistent with our BRD4 knockdown data (Fig. 1e,f) , treatment with a second shRNA oligonucleotide against BRD4 (Supplementary Fig. 1g ) and BRD4 inhibition with JQ1 treatment (Supplementary Fig. 1i ) also resulted in a significant decrease in the TNF-α -inducible MMP9 and CCL2 eRNA and mRNA levels. This role for BRD4 in the regulation of TNFinduced expression of eRNAs and tumor-promoting genes is consistent with our previous observations that mutp53 is also required to support TNF-α -inducible eRNA and mRNA expression levels in SW480 colon cancer cells 44 . Collectively, these data suggest that BRD4 acts coordinately with mutp53 at active enhancers to support potent levels of eRNA synthesis and gene expression in response to chronic TNF-α signaling.
BRD4 associates with RNAs synthesized from genomic regions occupied by BRD4. Given the overlap between BRD4 enrichment and eRNA synthesis in response to chronic TNF-α signaling and the previously described BRD4 association with RNA Pol II elongation complexes 34 , we examined whether BRD4 associates with RNAs by performing ultraviolet-cross-linked RNA immunoprecipitation (UV-RIP) in SW480 cells ( ± TNF-α ). BRD4 mRNA and protein levels were unaffected by chronic TNF-α treatment in this cell line ( Supplementary Fig. 2a ). In TNF-α -treated cells, a BRD4 antibody specifically coimmunoprecipitated eRNAs produced from the MMP9, CCL2, CSF2, and TNFAIP3 enhancers, but not the TFAP2A and MPP7 enhancers ( Fig. 2a and Supplementary  Fig. 2b ), despite the TFAP2A and MPP7 eRNAs being expressed at comparable or higher levels relative to the MMP9, CCL2, CSF2, and TNFAIP3 eRNAs ( Fig. 2c and Supplementary Fig. 2c ). We also found that BRD4 associated with the MMP9 and CCL2 mRNAs, but not the TFAP2A and MPP7 mRNAs, in response to chronic TNF-α signaling (Fig. 2b) . Under uninduced conditions, BRD4 did not associate with any of the analyzed RNAs (Fig. 2a,b and Supplementary Fig. 2b ). The specific association of BRD4 with RNAs in response to chronic TNF-α signaling is consistent with the significantly higher TNF-α -induced versus uninduced RNA , and BRD4 enrichment at the enhancer (amplicon A) and nonspecific (amplicon B) regions of the MMP9 and CCL2 gene loci in SW480 cells expressing LacZ (Ctrl) or p53 shRNA and treated with TNF-α for 16 h. c, log 2 -transformed fold change in GRO-seq signal in response to TNF-α signaling at intergenic regions enriched for H3K27ac that were co-bound or unbound by both BRD4 and p53 R273H,P309S . Box plots enclose values between the first and third quartiles, midlines show medians, and whiskers extend to data points within 1.5 times the interquartile range from the box. Statistical significance was determined by Mann-Whitney U test. d, qRT-PCR and immunoblot analysis of SW480 cells expressing control shRNA (Ctrl) or two BRD4 shRNAs (BRD4-1, BRD4-2) and treated with TNF-α for 0 or 16 h (n = 3 experiments). Uncropped blots are shown in Supplementary Dataset 1. e, ChIP-qPCR analysis of BRD4 binding in SW480 cells treated as described in d at the MMP9 and CCL2 gene loci. In b and e, data represent the mean and s.e.m. of n = 2 independent ChIP-qPCR experiments that are representative of at least three replicates. f, qRT-PCR analyses of MMP9 and CCL2 eRNAs and mRNAs in SW480 cells treated as described in d. Expression levels shown after TNF-α treatment are relative to the levels before treatment, and data represent the mean and s.e.m. of n = 3 independent experiments. Statistical significance was determined by two-tailed Student's t test. *P < 0.05.
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expression levels ( Fig. 2c and Supplementary Fig. 2c) . Notably, BRD4-RNA associations were also consistent with BRD4 binding levels, which were found to be significantly higher at the MMP9 and CCL2 enhancers relative to the TFAP2A and MPP7 enhancers and transcription start sites (TSSs) in response to chronic TNF-α signaling (Fig. 2d) . In addition, the TNF-α -induced associations of BRD4 with the CSF2 and TNFAIP3 eRNAs ( Supplementary   Fig. 2b ) paralleled the high levels of BRD4 binding at the corresponding enhancers (Supplementary Fig. 2c ).
We next explored direct interactions between recombinant fulllength (FL) BRD4 and several RNAs and found that BRD4 interacted with the in vitro-transcribed MMP9 and CCL2 eRNAs, MEG3 long noncoding RNA (lncRNA), and CDKN1A (p21) exonic RNA ( Supplementary Fig. 2d ). Together with our UV-RIP analyses, these (Fig. 3a) . Quantification of the RNA EMSA with increasing doses of BRD4-FL revealed that ~80% of the MMP9 eRNA was bound by BRD4-FL at the highest titration of BRD4-FL ( Supplementary Fig. 2e ). Competition EMSAs showed that BRD4 binding to the labeled MMP9 eRNA probe was specifically competed by excess amounts of unlabeled CCL2 eRNA (Fig. 3b) , but comparable amounts of cold MMP9 single-stranded DNA (ssDNA) were notably less efficient (Fig. 3b) , which demonstrates that BRD4 binds preferentially to RNA in vitro.
To identify the eRNA-interacting domains of BRD4, we performed RNA pulldowns using BRD4 deletion mutants (Fig. 3c ) and in vitro-transcribed MMP9 and CCL2 eRNAs. BRD4-FL and the naturally existing BRD4 isoform spanning amino acids 1-722 48 bound comparably to the MMP9 and CCL2 eRNAs (Fig. 3d) . We next tested the contributions of the BRD4 BDs, given that these domains are located within the eRNA-interacting BRD4 (1-722) protein. Notably, we found a nearly complete loss of binding between BRD4 that was devoid of both BDs (BRD4 Δ BD1/2; Fig. 3c ) and the MMP9 and CCL2 eRNAs (Fig. 3d) . Similarly, in RNA EMSAs, radiolabeled MMP9 eRNA did not display a prominent mobility shift with increasing titrations of BRD4 Δ BD1/2 protein (Fig. 3e) . Specifically, less than 5% of the labeled eRNA was bound by BRD4 Δ BD1/2, as compared with 80% by BRD4-FL ( Fig. 3e and Supplementary Fig. 2e ).
We next tested whether an individual BRD4 BD (BD1 or BD2; Fig. 3c ) is sufficient to support BRD4-eRNA interactions. We found that neither BD1 nor BD2 was able to bind to the MMP9 and CCL2 eRNAs as strongly as the BRD4 (1-722) protein (Fig. 3f) . In comparison, a BRD4 protein (BRD4 BD1/2; Fig. 3c ) consisting of both BDs and the linker sequence that joins them showed a level of eRNA binding that was comparable to that of BRD4 (1-722) (Fig. 3f) . The tandem BDs (BD1/2) of the BET family members BRD2, BRD3, BRD4, and BRDT and the single BDs of the non-BET proteins BRG1 and BRD7 bound to MMP9 and CCL2 eRNAs, with the eRNA interaction levels of BRG1 and BRDT BDs being relatively lower than the BDs of other proteins. Taken together, these findings demonstrate that BDs directly interact with eRNAs and that the tandem BRD4 BDs function cooperatively to facilitate BRD4-eRNA interactions.
eRNAs enhance BRD4 binding to acetylated histone H3 and H4 peptides and histone octamers. To investigate the importance of eRNA-BRD4 interactions in the regulation of BRD4 BD binding to acetylated histones, we carried out in vitro binding assays with unmodified or acetylated H3 and H4 histone peptides. As expected, BRD4-FL, but not BRD4 Δ BD1/2, bound more strongly to H3K27ac-and H4K16ac-modified versus unmodified peptides (Fig. 4a,b) . Notably, the binding of BRD4-FL to acetylated H3K27 and H4K16 peptides was increased in the presence of MMP9 eRNA (Fig. 4a,b ). In addition, eRNAs did not promote BRD4 binding in the absence of BRD4 interactions with acetylated peptides, as demonstrated by the inability of eRNAs to support BRD4-FL binding to unmodified histone H3 and H4 peptides and the lack of an eRNA effect on BRD4 Δ BD1/2 binding to acetylated H3K27 and H4K16 peptides (Fig. 4a,b) .
We also examined the effects of eRNAs on BRD4 binding to histone octamers that were either unacetylated or acetylated by the histone acetyltransferase p300 ( Supplementary Fig. 3a ). As predicted, p300 efficiently acetylated the histone octamers, as demonstrated by increased acetylation of H3K27 and H3K9, and little to no acetylation was detected in the absence of p300 or acetyl-CoA (Fig. 4c) . We coupled acetylated histone octamers to magnetic beads using H3K27ac and H3K9ac antibodies and then incubated them with BRD4 in the presence or absence of MMP9 eRNA. Similar to the histone peptide binding assay results, we found that MMP9 eRNA increased BRD4-FL but not BRD4 Δ BD1/2 binding to acetylated histone octamers (Fig. 4c) . Enhanced binding of BRD4 to acetylated histone peptides and octamers was confirmed in the presence of the CCL2 eRNA ( Supplementary Fig. 3b,c) . Moreover, eRNA titration experiments revealed that several concentrations of the MMP9 eRNA enhanced BRD4 binding to acetylated histone octamers, whereas high molar ratios of MMP9 eRNA inhibited BRD4 binding ( Supplementary Fig. 3d ).
To gain insight into the steady-state binding of BRD4 to acetylated histone H3 in the presence or absence of eRNAs, we carried out surface plasmon resonance (SPR) analyses. Sensorgrams resulting from various concentrations of BRD4 BD1/2 protein flowed over immobilized H3K27ac-modified peptides in the presence or absence of MMP9 eRNA showed that the amount of bound BRD4 BD1/2 was enhanced in the presence of the eRNA to yield an absolute level of binding that was approximately threefold higher than that observed in the absence of eRNA (Fig. 4d ). An appreciable dissociation was not detected, as BRD4 BD1/2 remained bound to the H3K27ac-modified peptide during the time course of the experiments (Fig. 4d) . Notably, the sensorgrams also demonstrated that all of the concentrations of BRD4 BD1/2 reached a significantly higher maximum binding capacity (R max ) in the presence versus the absence of eRNA (Fig. 4e) . These biophysical and biochemical findings indicate that eRNA interactions with BRD4 BDs are pivotal for the enhanced binding of BRD4 to acetylated histones in vitro.
eRNAs modulate BRD4 enhancer occupancy to maintain enhancer and gene activation. To investigate the biological significance of BRD4-eRNA interactions, we first employed shRNAmediated knockdown of eRNAs in SW480 cells ( ± TNF-α ). qRT-PCR analysis showed that, relative to a non-targeting control, shRNAs that targeted the MMP9 (MMP9 eRNA-1) and CCL2 (CCL2 eRNA-1) eRNAs specifically decreased the TNF-α -induced levels of MMP9 and CCL2 eRNAs by approximately threefold and sixfold, respectively (Fig. 5a) . Notably, this decrease in MMP9 and CCL2 eRNA levels resulted in a threefold decrease in MMP9 and CCL2 mRNA levels, respectively, thereby revealing a direct role for these eRNAs in the induction of proinflammatory gene expression (Fig. 5a ). This reduction in TNF-α -induced MMP9 and CCL2 mRNA levels was further confirmed with a second shRNA targeting the MMP9 (MMP9 eRNA-2) and CCL2 (CCL2 eRNA-2) eRNAs ( Supplementary Fig. 4a ). Consistent with the specificity of the eRNA knockdown effects, depletion of the MMP9 and CCL2 eRNAs did not affect the eRNA and mRNA expression levels of CCL2 and MMP9, respectively ( Fig. 5a and Supplementary Fig. 4a ), or those of CPA4 and CYP24A1, which were also significantly induced following TNF-α treatment ( Supplementary Fig. 4b ). In addition, the gene-selective effects of the MMP9 and CCL2 eRNAs were not a result of altered mutp53 or BRD4 protein levels, which were found to be unaffected in the eRNA knockdown cells (Fig. 5b) .
We next performed ChIP-qPCR in TNF-α -treated MMP9 and CCL2 eRNA knockdown cells to determine whether these eRNAs have a direct role in the regulation of BRD4 enhancer occupancy. Notably, BRD4 binding in the MMP9-and CCL2-eRNA-depleted cells was significantly reduced at the MMP9 and CCL2 enhancer regions (46 and 49%, respectively; Fig. 5c ). Consistent with the
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specificity of eRNA function, MMP9 eRNA knockdown did not affect BRD4 binding at the CCL2 enhancer region, and vice versa (Fig. 5c ). The decrease in BRD4 binding following eRNA knockdown was consistent with a comparable reduction in RNA Pol II binding at the MMP9 and CCL2 enhancers (54% and 66%, respectively; Fig. 5c ), which is consistent with the previously described roles of BRD4 in supporting RNA Pol II binding 32, 33 . These results were further confirmed by treating SW480 cells with actinomycin D (Act D), which inhibits transcription without affecting BRD4 protein levels ( Supplementary Fig. 4c ). The reduced MMP9 and CCL2 eRNA levels following Act D treatment ( Supplementary Fig. 4d ) correlated with a notable decrease in TNF-α -induced BRD4 binding by 61% and 77% at the MMP9 and CCL2 enhancers, respectively ( Supplementary Fig. 4e ).
We next investigated the effects of eRNAs on BRD4-dependent eRNA and mRNA expression levels. shRNA-resistant BRD4-FL or BRD4 Δ BD1/2 constructs were transiently transfected in SW480 cells that stably expressed shRNAs against MMP9 or CCL2 eRNA and BRD4. Relative to the vector control, both BRD4-FL and BRD4 Δ BD1/2 reconstituted BRD4 mRNA and protein levels in BRD4-knockdown cells (Fig. 5d ). As expected, BRD4-FL, but not BRD4 Δ BD1/2, was able to rescue TNF-α -inducible MMP9 and CCL2 eRNA and mRNA expression levels in the BRD4 single-knockdown cells (Fig. 5e) . Notably, however, 
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the ability of BRD4-FL to rescue CCL2 eRNA and mRNA expression levels in the CCL2 eRNA and BRD4 double-knockdown cell lines was significantly (two-to threefold) less efficient. Moreover, BRD4-FL was comparably less efficient at rescuing MMP9 eRNA and mRNA levels in the BRD4 and MMP9 double-knockdown cells than in the BRD4 single-knockdown cells (Fig. 5e ). BRD4 Δ BD1/2 was unable to rescue MMP9 and CCL2 eRNA and mRNA levels in the eRNA and BRD4 double-knockdown cells (Fig. 5e) . These rescue experiments, taken together with our in vitro analyses, demonstrate that eRNAs are pivotal for the regulation of BRD4 enhancer binding that supports BRD4-dependent enhancer transcription and gene activation in response to chronic TNF-α signaling.
Discussion
BRD4 localizes at enhancers to regulate the expression of oncogenes that include MYC, which has important implications in human disease [19] [20] [21] 49, 50 . Our findings advance understanding of the role of BRD4 in human cancer by identifying this co-activator at enhancers that are co-occupied by the oncogene mutp53 in response to chronic immune signaling. Among the enhancers cobound by mutp53 and BRD4 are several enhancers that are regulated by mutp53 and NF-κ B and are linked to the activation of a proinflammatory gene expression program that leads to increased colon cancer cell invasion potential 44 . In support of a functional relationship between mutp53 and BRD4, we found that BRD4 formed direct interactions and cellular associations with mutp53 and was simultaneously bound with mutp53 at active enhancers in response to chronic TNF-α signaling. In addition, mutp53 affected BRD4 recruitment at a subset of enhancers following chronic immune signaling. Moreover, our data support a role for BRD4 in regulating the activation of mutp53 and BRD4 co-bound enhancers, as demonstrated by the significantly higher eRNA levels present at BRD4 and mutp53 co-bound versus unbound enhancers and the downregulation of eRNA levels following BRD4 knockdown or inhibition by JQ1. Given the mutp53 and BRD4 cooperativity in colon cancer cells that we observed, future studies testing BRD4 regulation of mutp53-dependent gene expression programs in other systems are likely to be clinically relevant as a result of the widespread roles of mutp53 and BRD4 in cancer and the potential for pharmacological inhibition of BRD4.
eRNAs interact with BRD4 to affect transcriptional activation. Given the prevalence of eRNAs in various cell types and in response to stimuli [36] [37] [38] [39] [40] [41] [42] [43] [44] , we can envision a number of functions for eRNAs in transcriptional regulation. Our results provide strong evidence that eRNAs stimulate transcription by enhancing BRD4 binding to acetylated histones. Specifically, we found that eRNAs formed physiological associations and direct interactions with the tandem BDs of BRD4, which in turn promoted enhanced BRD4 binding to acetylated forms of histone H3 and H4 peptides, acetylated histone octamers, and active enhancers. Notably, eRNA depletion resulted in a marked decrease in the enhancer binding of BRD4, which coincided with reduced RNA Pol II occupancy and downregulation of inflammation-induced gene expression in colon cancer cells. Our findings also underscore the importance of BRD4-eRNA interactions in regulating enhancer-dependent gene activation by revealing the recovery of eRNA and tumor-promoting gene expression by BRD4-FL (but not BRD4 Δ BD1/2) in BRD4 single-knockdown, but not BRD4 and eRNA double-knockdown, cells. Taken together, our results support a model (Fig. 6 ) for a positive feedback loop in which eRNAs are involved in the cis recruitment of BRD4 at mutp53-bound enhancers for augmented enhancer and gene activation. Furthermore, this model supports the concept of functional convergence between histone modifications and eRNAs, which emphasizes the fact that eRNAs affect the binding potential of BRD4 after it has bound to acetylated histones. This observed cooperativity between epigenetic mechanisms is consistent with previous studies showing that the methyl-lysine-recognition chromodomain of CBX7CD binds lncRNA ANRIL 51 and further suggest that eRNAs, similar to lncRNAs, are likely to function through chromatin effector domains to affect gene regulation. Notably, our findings did not rule out the possibility of eRNAs regulating other BRD4 functions, including its histone-modifying activity 52 . We found that BRD4 bound to a broad spectrum of RNAs, which suggests that it has a promiscuous relationship with RNAs. Although RNA sequence did not appear to contribute to the specificity of BRD4-RNA interactions, and we cannot rule out RNA structural contributions, we have found that BRD4 forms associations with RNAs in an enhancer/locus-specific manner. These results are supported by our BRD4 UV-RIP, BRD4 ChIP-seq, and GRO-seq analyses, which demonstrate the ability of BRD4 to form associations with RNAs that are produced specifically from genomic regions highly enriched for BRD4. This observation is consistent with a recent study showing that CBP also associates with RNAs that are produced at sites at which high levels of CBP binding exist 47 . Our findings further demonstrate the ability of BRD4-FL to reconstitute MMP9 and CCL2 eRNA levels in the CCL2 and MMP9, but not the MMP9 and CCL2, eRNA and BRD4 double-knockdown cells, Following chronic TNF-α signaling, NF-κ B recruits mutp53 to a subset of enhancers, as we have previously described 44 . We found that BRD4 formed direct interactions with mutp53 and was recruited by mutp53 to these mutp53/NF-κ B-activated enhancers following chronic immune signaling. Subsequently, eRNAs synthesized from the activated enhancers bound to the BDs of BRD4 to enhance its binding to acetylated chromatin. This stabilization of BRD4 at active enhancers contributed to TNF-α -induced production of eRNAs and potent expression of the nearby tumor-promoting genes.
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respectively, which is further consistent with enhancer-and locusspecific eRNA-BRD4 associations.
eRNAs interact with the highly conserved acetyl-lysine-recognition bromodomains. The ability of eRNAs to regulate the chromatin binding and transcriptional co-activator functions of BRD4 could be widespread, as BDs are evolutionarily conserved 12 and our mapping revealed them to be the eRNA-interacting domains of BRD4. In support of this possibility, we found that the tandem BDs of all BET family members and the single BDs of non-BET proteins BRG1 and BRD7 formed interactions with eRNAs. Our observation of variable levels of RNA binding by various BDs is consistent with known differences in BD structure and conformation, which are linked to differential BD interactions with acetylated residues 53 . Moreover, given the development of inhibitors that are specific to the BDs of various members of the BET family 54 , eRNAs that bind to BDs could be potent therapeutic targets for repressing protumorigenic gene expression programs.
Our observation that eRNAs enhance BRD4 binding to acetylated histones and octamers suggests that eRNAs are likely to interact with the BD in a region that is independent of the acetyllysine-recognition domain. Although BDs are categorized into eight distinct classes on the basis of their diverse structures, they share four conserved α -helices that are connected to one another by loops of variable length 15, 53 . Conserved amino acids located in these loops facilitate the docking of acetylated lysine residues, and a patch of basic amino acids surrounds the acetyl-binding pocket, further prompting interactions with acetylated substrates 10, 53 . It is possible that this positively charged patch could facilitate interactions with negatively charged nucleic acids, including eRNAs. This possibility is consistent with recent studies that have shown that the positively charged patch facilitates interactions of the BRDT BD1 55 and the BRG1/human BRM (hBRM) BDs 56 with DNA. Furthermore, point mutations in the positively charged patch of hBRM BD were found to substantially reduce the binding of hBRM to DNA without disrupting its interactions with acetylated peptides 56 . This finding suggests that BD interactions with nucleic acids are likely to occur outside of the acetyl-lysine-recognition domain and could therefore allow RNA and DNA interactions that enhance BD associations with acetyl-lysines. In addition, differences in the amino acids in the BD loops could contribute to variations in the electrostatic charge that, together with variable structural and conformational contributions, may predict the variable levels of interaction that we observed between eRNAs and different BDs assessed in our study.
Our demonstration that each of the tandem BRD4 BDs is required to reconstitute interactions with eRNAs, as well as the importance of bivalent interactions of BDs with acetylated lysines and eRNAs, is consistent with previous reports revealing the importance of multivalency in chromatin regulation. Specifically, the overall affinity and specificity of chromatin binding can be enhanced by multiple chromatin-interacting domains in a single chromatin reader or through multiple chromatin-interacting proteins that are present in multiprotein complexes 57 . Consistent with this, the BDs of the BET family exhibit a modest affinity for monoacetylated lysine that is substantially increased when the BDs are anchored to multiple acetylation sites 10, 14, 58 . Future studies will be needed to extend the implications of BD-RNA interactions and to determine how BDs engage these epigenetic modifiers to transduce downstream function.
Taken together, our findings are consistent with the emerging notion that eRNAs are functional molecules, rather than merely reflections of enhancer activation or simply transcriptional noise. Our results provide mechanistic insights into the role of eRNAs that directly interact with BRD4 at active enhancers, leading to increased RNA Pol II binding, eRNA synthesis, and the transcription of proinflammatory genes. These findings provide a framework for understanding eRNAs and their convergence with histone modifications in the regulation of transcriptional co-activators.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41594-018-0102-0.
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Methods
Cell culture and treatments. Human colorectal adenocarcinoma SW480 cells and human embryonic kidney 293 T (HEK293T) cells were purchased from American Type Culture Collection (ATCC) and grown in Dulbecco's modified Eagle medium (DMEM, Gibco) supplemented with 10% fetal bovine serum (FBS, Gibco). SW480 cells that stably and inducibly express short hairpins against LacZ or p53 were kindly provided by X. Chen (University of California, Davis), grown in standard DMEM medium containing penicillin and streptomycin (Gemini Bio-Products), 1.5 μ g ml −1 puromycin (Sigma), and induced with 1 μ g ml −1 doxycycline (Sigma). Lentivirus infected SW480 cells were propagated in growth medium containing DMEM, 10% FBS, 100 units ml −1 penicillin, 100 μ g ml −1 streptomycin, and 1.5 μ g ml −1 puromycin. All cell lines were tested for mycoplasma contamination. For experiments with TNF-α treatment, the indicated cells were treated with 12.5 ng ml −1 recombinant TNF-α (Shenandoah Biotechnology) for the indicated time points before harvesting for gene expression or ChIP analyses. SW480 cells were treated with a final concentration of 500 nM JQ1 (Cayman Chemical), 2 μ g ml
Act D (ApexBio), or vehicle (DMSO, Fisher Scientific) before harvesting for gene expression and immunoblot analyses.
Immunoblotting. Protein samples were incubated at 95 °C for 5 min, separated by SDS-PAGE, and transferred to PVDF membranes (EMD Millipore) that were probed with the indicated antibodies. Reactive bands were detected by ECL (Thermo Scientific Pierce) and exposed to Blue Devil Lite ECL films (Genesee Scientific) or visualized by LI-COR (LI-COR Biosciences).
Antibodies. Antibodies used for ChIP assays were obtained commercially as follows: anti-BRD4 (A301-985A100, 1 μ g) from Bethyl laboratories; anti-p53 (DO1, sc126, 1 μ g), anti-RNA Pol II (N20, sc899, 1 μ g), anti-IgG (sc2027, 1 μ g) from Santa Cruz Biotechnology. Antibodies used for immunoblotting were obtained as follows: anti-BRD4 (1:3,000 dilution) from Bethyl laboratories, antiH3K27ac (ab4729, 1:5,000 dilution) from Abcam; anti-H3K9ac (13-0020, 1:5,000 dilution) from EpiCypher; and anti-p53 (DO1, sc126, 1:2,000 dilution) and anti-β -actin (sc47778, 1:2,000 dilution) from Santa Cruz Biotechnology.
Lentivirus production and transduction. pLKO.1 TRC control and target shRNA plasmids were generated with annealed primers to knockdown BRD4 and the MMP9 and CCL2 eRNAs. shRNA primers used in this study are listed in Supplementary Table 1 . For lentivirus production and transduction, 50-60% confluent HEK293T cells were transfected with Lipofectamine 3000 (Invitrogen) with TRC control, target shRNAs, and packaging plasmids psPAX2 and pMD2.G. Virus-containing medium was collected 48 and 72 h post transfection, filtered with a 0.45-μ m pore size filter, and used for viral infection. SW480 cells were transduced with the viral supernatants containing 8 μ g ml −1 polybrene (Sigma-Aldrich). After 8 h infection, virus-containing medium was removed and replaced with fresh medium. After 48 h, puromycin was added at a final concentration of 1.5 μ g ml −1
. Cells were cultured for an additional 72 h before harvesting the cells for qRT-PCR and immunoblot to confirm successful knockdown efficiency.
In vitro RNA synthesis. Primers were designed to amplify desired genomic regions that correspond to maximal eRNA (GRO-seq) peaks at MMP9 and CCL2 enhancers. The MEG3 and p21 exonic sequences were identical to those used in a previous study 47 . Primers sequences can be found in Supplementary Table  2 . The T7 promoter sequence was included in the forward primer and genomic fragments were PCR amplified from HeLa genomic DNA (NEB), confirmed by sequencing, and subsequently used for RNA synthesis using T7 RiboMAX Express Large-Scale RNA Production System (Promega). Synthesized RNAs were purified per manufacturer's instructions and quantitated by Nanodrop (Invitrogen). RNA probes were refolded by incubation at 95 °C for 5 min followed by snap-cooling on ice for 5 min. Cold RNA refolding buffer (10 mM Tris-HCl at pH 7, 100 mM KCl, 10 mM MgCl 2 ) was then added and the samples were transferred to an icecold metal rack. RNAs were allowed to refold by warming the sample to room temperature (20-25 °C) for 20-30 min.
RNA purification and qRT-PCR. Total RNA was extracted with TRIzol LS reagent (Invitrogen) from SW480 stably expressing control, BRD4, or CCL2 and MMP9 eRNA shRNAs and treated with 12.5 ng ml −1 TNF-α for the indicated time points. Total RNA (0.5-1 μ g) was used for cDNA synthesis using ProtoScript II First Strand cDNA Synthesis Kit (NEB) with random hexamers. PCR reactions were performed on an Applied Biosystems Step One Plus real-time PCR systems using SYBR Green PCR Master Mix (Applied Biosystems) in duplicate using samples from at least three independent cell harvests and the specificity of amplification was examined by melting curve analysis. The relative levels of eRNA and mRNA expression were calculated according to the (Δ Δ Ct) method and individual expression data was normalized to GAPDH. The gene expression levels determined after TNF-α treatment are relative to the levels before TNF-α treatment. Primers for qRT-PCR are listed in Supplementary Table 3 .
Ultraviolet-RNA Immunoprecipitation (UV-RIP). SW480 cells treated with TNF-α for 0 or 16 h were crosslinked by UV irradiation (150 mJ per cm 2 at 254 nm) using a Stratalinker and lysed in RIP lysis buffer (25 mM HEPES-KOH at pH 7.5, 150 mM KCl, 0.5% NP40, 1.5 mM MgCl 2 , 10% glycerol, 1 mM EDTA, 0.4 U RNase inhibitor (Promega), protease inhibitor cocktails (PICs)) on ice for 30 min. Cleared cell lysates were used for IP with BRD4 and IgG-antibody bound Protein A Dynabeads (Invitrogen) overnight. Beads were subsequently washed three times with RIP lysis buffer and RNA samples were eluted using TRIzol LS reagent. cDNA samples were prepared as described above and analyzed by qRT-PCR primers listed in Supplementary Table 3 .
Histone peptide binding assays. Unmodified H3 (21-44), K27ac-modified H3 (21-44), unmodified H4 (1-25), or K16ac-modified H4 (1-25) peptides (Innopep) were immobilized on Dynabeads MyOne Streptavidin C1 (Life Technologies) and subsequently incubated with 200 ng of recombinant FLAG-BRD4 FL or FLAG-BRD4 BD1/2 in the absence or presence of 0.2 nM refolded MMP9 or CCL2 eRNA in binding buffer (150 mM NaCl, 20 mM HEPES-KOH at pH 7.9, 0.1% NP40, 0.25 mg ml −1 bovine serum albumin (BSA), 1 mM sodium butyrate, 1 mM PMSF, PICs, RNase inhibitor) for 4 h at 4 °C. Beads were washed ten times with binding buffer containing 400 mM NaCl. Bound proteins were eluted in sample buffer and analyzed by SDS-PAGE and immunoblotting.
Histone acetyltransferase (HAT) assays. Recombinant histone octamers (0.5 μ g) that were purified as previously described 59 were incubated with p300 (30 ng) and acetyl-CoA (20 μ M) in reaction buffer (50 mM HEPES pH 7.8, 30 mM KCl, 0.25 mM EDTA, 5.0 mM MgCl2, 5.0 mM sodium butyrate, 2.5 mM DTT). Reactions were incubated at 30 °C for 30 min, resolved by SDS-PAGE, and analyzed by immunoblotting.
Histone octamer binding assays. p300-acetylated histone octamers were isolated by incubating the HAT reactions with H3K9ac and H3K27ac antibody-coupled Protein A Dynabeads in binding buffer (150 mM NaCl, 50 mM Tris-HCl at pH 8.0, 0.1% NP40, 1 mM sodium butyrate, 1 mM PMSF, PICs) for 3 h at 4 °C. Following the incubation, the acetylated histone octamer bound beads were washed three times with binding buffer and then incubated with 200 ng of recombinant FLAG-BRD4 FL or FLAG-BRD4 BD1/2 in the absence or presence of 0.2 nM or increasing doses (0.06 nM to 2 nM) of refolded eRNA in binding buffer with 1% BSA for 12 h at 4 °C. The protein complexes were washed eight times with wash buffer (400 mM NaCl, 50 mM Tris-HCl at pH 8.0, 0.1% NP40, 0.5% BSA, 1 mM Sodium butyrate, 1 mM PMSF, PICs). Bound proteins were eluted in sample buffer and analyzed by SDS-PAGE and immunoblotting with the indicated antibodies.
Surface plasmon resonance (SPR) assays. Sensorgrams were recorded on a BIAcore 3000 instrument using streptavidin (SA) chips. Biotinylated H3K27ac histone peptide was immobilized on the SA chip in binding buffer (150 mM NaCl, 20 mM HEPES-KOH at pH 7.9, 0.1% NP40). Sensorgrams were run in the automatic subtraction mode using flow cell 1 (FC 1) as an unmodified reference. Data was collected for FCs 2, 3, and 4, which contained varying amounts of BRD4 BD1/2 and in the presence or absence of 0.2 nM refolded MMP9 eRNA with 100 RU immobilized on FC2, 200 RU on FC3, and 400 RU on FC4. Injections were made using the kinject injection mode with a 3-min contact time and a 3-min dissociation phase, at a flow rate of 50 μ l min −1
. The running buffer used for the binding experiments was 150 mM NaCl, 20 mM HEPES-KOH at pH 7.9, 0.1% NP40. The data was analyzed using the BIA Evaluation 4.1 software.
Co-immunoprecipitation. Assays were performed using whole cell lysates prepared from SW480 cells that were treated with 12.5 ng ml −1 TNF-α for 0 or 16 h. Cleared lysates were first incubated with indicated antibodies for 2 h at 4 °C followed by an additional 2-h incubation with Protein A Sepharose (Rockland). Beads were washed with wash buffer (20 mM Tris-HCl at pH 7.9, 0.1% NP40, 150 mM KCl) five times and analyzed by immunoblotting.
ChIP and ChIP-Seq. BRD4 ChIP assays were performed using SW480 cells that were (i) untreated or treated with 12.5 ng ml −1 TNF-α for the indicated time points or (ii) transduced with indicated shRNAs and treated with 12.5 ng ml −1 TNF-α for 0 or 16 h. Cells were sequentially cross-linked using 6 mM DSG (disuccinimidyl glutarate; ProteoChem) for 30 min and a final concentration of 1% formaldehyde for 10 min at room temperature (20-25 °C) and stopped with 125 mM glycine (Fisher Scientific). Cells were lysed in lysis buffer (20 mM Tris-HCl at pH 7.5, 300 mM NaCl, 2 mM EDTA, 0.5% NP40, 1% Triton X-100, 1 mM PMSF, PICs) and incubated on ice for 30 min. The resuspended cells were then dounced in an ice-cold homogenizer. Nuclear pellets were collected and resuspended in shearing buffer (0.1% SDS, 0.5% N-lauroylsarcosine, 1% Triton X-100, 10 mM Tris-HCl at pH 8.1, 100 mM NaCl, 1 mM EDTA, 1 mM PMSF, PICs). Isolated chromatin was fragmented to an average size of 200-600 bp with a bioruptor Pico (Diagenode). Precleared chromatin was immunoprecipitated overnight at 4 °C and immunocomplexes were collected with protein A Dynabeads. The immunocomplexes were washed eight times in wash buffer (50 mM HEPES-KOH at pH 7.6, 500 mM LiCl, 1 mM EDTA, 1% NP40, 0.7% sodium deoxycholate, 1 mM PMSF, PICs), followed by two 1 × TE washes, and eluted in elution buffer (50 mM
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Tris-HCl at pH 8.0, 10 mM EDTA, 1% SDS), crosslinks were reversed at 65 °C for 4 h or overnight, and DNA was purified using DNA Clean & Concentrator Kit according to the manufacturer's instructions. PCR reactions were performed on an Applied Biosystems Step One Plus real-time PCR systems using SYBR Green PCR Master Mix in duplicate using samples from at least three independent cell harvests and the specificity of amplification was examined by melting curve analysis. The relative amounts of ChIP DNA were quantified relative to inputs. Primers for ChIP-quantitative PCR are listed in Supplementary Table 4 . Sequential ChIP experiments were performed exactly as described above with minor modifications. Specifically, 150 μ g of sheared chromatin was used to perform the IP. Following the washes after the first IP, immunocomplexes were eluted in re-IP elution buffer (50 mM Tris-HCl at pH 8.0, 1% SDS, 1 mM EDTA, 1 mM DTT, 1 mM PMSF, PICs) and diluted tenfold in dilution buffer (16.7 mM Tris-HCl at pH 8.0, 167 mM NaCl, 0.01% SDS, 1% Triton X-100, 1.2 mM EDTA, 1 mM PMSF, PICs). The second IP was performed with indicated antibodies overnight at 4 °C, followed by additional washes and the final elution as described above.
For ChIP-seq experiments, the IPs were performed as described. The eluted ChIP DNA was quantified using a Qubit 2.0 fluorometer (Invitrogen), and 2-5 ng of ChIP DNA was used to prepare the sequencing libraries from two biological replicates using the TruSeq ChIP Sample Prep Kit according to the manufacturer's instructions (Illumina). Briefly, ChIP DNA was end-repaired and adaptors were ligated to the ends of the DNA fragments. Adaptor-ligated ChIP DNA fragments with average size of 350 bp were used to construct libraries and single-end sequenced (50 bp) on Illumina HiSeq 4000. Sequencing reads were mapped to the hg38 human genome using Bowtie2 software 38 and default parameters. The mapped reads were then processed to generate Tag Directories using HOMER PCR duplications were removed, and only uniquely mapped reads were kept for further analysis. The genome browser files for the resulting reads were generated by using makeUCSCfile module from HOMER. Enriched regions for BRD4 were called using find Peaks module from HOMER by using preset options, factor or histone styles respectively and compared to the corresponding inputs. Deeptools were used to generate heat maps. De novo motif analysis was performed using the BRD4/mutp53 co-bound enhancer regions using findMotifsGenome.pl of Homer with ± 100-bp window relative to the peak center.
Purification of recombinant proteins. Mutant p53 R273H was generated by site-directed mutagenesis (Agilent Technologies). FLAG-BRD4 BD1/2, BD1, BD2 were cloned into pET11d bacteria expression vector using NdeI and BamHI sites after amplification from BRD4 cDNA. His-tagged tandem BDs (BD1/2) of BRD2, BRD3, BRD4, and BRDT as well as the single BDs of BRG1 and BRD7 were cloned into pET6His bacteria expression vector using BamHI and EcoRI sites. p53 and BD constructs were expressed in E. coli and purified on FLAG M2 agarose beads (Sigma) or TALON metal affinity resin (Clontech). The FLAG p300, BRD4 FL, and Δ BD1/2 proteins were expressed in Sf9 cells and purified on FLAG M2 agarose. Primers used for cloning are listed in Supplementary Table 5 .
In vitro pull-down RNA binding assays. FLAG-and His-tagged proteins were incubated with 500 ng of refolded RNA while rotating at 4 °C for 1 h in RNA binding buffer (20 mM Tris-HCl at pH 7.4, 100 mM KCl, 0.2 mM EDTA, 0.05% NP40, 0.4 U RNase inhibitor, PICs). Protein-RNA complexes were recovered using FLAG M2 agarose beads or TALON resin for 1 h at 4 °C. Beads were washed three times with RNA wash buffer (20 mM Tris-HCl at pH 7.4, 200 mM KCl, 0.2 mM EDTA, 0.05% NP40, 0.4 U RNase inhibitor, PICs) and RNA samples were eluted using Trizol LS reagent. Purified RNA samples were resolved on a denaturing 5% TBE urea gel and stained with SYBR gold for 30 min before imaging using a Typhoon phosphorimager or LI-COR.
RNA electrophoretic mobility shift assays. EMSAs were performed following established protocols 60 . Binding reactions were performed in 1 × RNA EMSA buffer (20 mM Tris-HCl at pH 7.4, 100 mM KCl, 1 mM EDTA, 1% glycerol, 0.05% NP40, 0.5 mM ZnCl 2 , 0.1 mg ml −1 BSA (Fisher), 0.1 mg ml −1 yeast tRNA (Sigma), 2 mM DTT, 0.4 U RNase inhibitor). The binding reactions were initiated by adding different doses (0.3-1.5 μ g) of FLAG-BRD4 protein in the presence of 12,000 cpm refolded RNA and allowed to proceed for 30 min at 4 °C. Reactions were loaded immediately on 6% native polyacrylamide gels that were pre-run for 1 h at 100 V in 0.5X TBE at 4 °C. The gel was run for 4 h at 100 V and exposed to autoradiography screen before imaging with Typhoon phosphorimager. For competition assays, 0, 50, 150, or 450 nM of unlabeled RNA or ssDNA was added in addition to the 32 P radiolabeled RNA.
Reporting Summary. Further information on experimental design is available in the Nature Research Reporting Summary linked to this article.
Data availability. All sequencing data that support the findings of this study have been deposited in the Gene Expression Omnibus (GEO) and are accessible through GEO series accession numbers GSE102796 and GSE110473. All other relevant data are available from the corresponding author upon reasonable request. Life Sciences Reporting Summary Nature Research wishes to improve the reproducibility of the work that we publish. This form is intended for publication with all accepted life science papers and provides structure for consistency and transparency in reporting. Every life science submission will use this form; some list items might not apply to an individual manuscript, but all fields must be completed for clarity.
For further information on the points included in this form, see Reporting Life Sciences Research. For further information on Nature Research policies, including our data availability policy, see Authors & Referees and the Editorial Policy Checklist.
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